Read about the progress of individual NINDS PDBP projects and learn about presentations and workshops that are relevant to the PDBP.
Regional Structural Hippocampal Differences Between Dementia with Lewy Bodies and Parkinson's Disease.

  • de Schipper LJ
  • Hafkemeijer A
  • van der Grond J
  • Marinus J
  • Henselmans JML
  • van Hilten JJ
New evidence on the management of Lewy body dementia.

  • Taylor JP
  • McKeith IG
  • Burn DJ
  • Boeve BF
  • Weintraub D
  • Bamford C
  • Allan LM
  • Thomas AJ
  • O'Brien JT
Assessment of a prognostic MRI biomarker in early de novo Parkinson's disease.

  • Zeighami Y
  • Fereshtehnejad SM
  • Dadar M
  • Collins DL
  • Postuma RB
  • Dagher A
PARK2 and PARK7 Gene Polymorphisms as Risk Factors Associated with Serum Element Concentrations and Clinical Symptoms of Parkinson's Disease.

  • Sanyal J
  • Anirudhan A
  • Banerjee TK
  • Guha G
  • Ramakrishnan Veerabathiran
  • Murugesan R
  • Ahmed SSJS
  • Rao VR
Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.

  • Alcalay RN
  • Hsieh F
  • Tengstrand E
  • Padmanabhan S
  • Baptista M
  • Kehoe C
  • Narayan S
  • Boehme AK
  • Merchant K
Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts.

  • Iwaki H
  • Blauwendraat C
  • Leonard HL
  • Kim JJ
  • Liu G
  • Maple-Grødem J
  • Corvol JC
  • Pihlstrøm L
  • van Nimwegen M
  • Hutten SJ
  • Nguyen KH
  • Rick J
  • Eberly S
  • Faghri F
  • Auinger P
  • Scott KM
  • Wijeyekoon R
  • Van Deerlin VM
  • Hernandez DG
  • Gibbs JR
  • International Parkinson's Disease Genomics Consortium.
  • Chitrala KN
  • Day-Williams AG
  • Brice A
  • Alves G
  • Noyce AJ
  • Tysnes OB
  • Evans JR
  • Breen DP
  • Estrada K
  • Wegel CE
  • Danjou F
  • Simon DK
  • Andreassen O
  • Ravina B
  • Toft M
  • Heutink P
  • Bloem BR
  • Weintraub D
  • Barker RA
  • Williams-Gray CH
  • van de Warrenburg BP
  • Van Hilten JJ
  • Scherzer CR
  • Singleton AB
  • Nalls MA
Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging.

  • Adler CH
  • Beach TG
  • Zhang N
  • Shill HA
  • Driver-Dunckley E
  • Caviness JN
  • Mehta SH
  • Sabbagh MN
  • Serrano GE
  • Sue LI
  • Belden CM
  • Powell J
  • Jacobson SA
  • Zamrini E
  • Shprecher D
  • Davis KJ
  • Dugger BN
  • Hentz JG
Nocturnal gamma-hydroxybutyrate reduces cortisol awakening response and morning kynurenine pathway metabolites in healthy volunteers.

  • Dornbierer DA
  • Boxler M
  • Voegel CD
  • Stucky B
  • Steuer AE
  • Binz TM
  • Baumgartner MR
  • Baur DM
  • Quednow BB
  • Kraemer T
  • Seifritz E
  • Landolt HP
  • Bosch OG
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes.

  • Jack CR
  • Wiste HJ
  • Botha H
  • Weigand SD
  • Therneau TM
  • Knopman DS
  • Graff-Radford J
  • Jones DT
  • Ferman TJ
  • Boeve BF
  • Kantarci K
  • Lowe VJ
  • Vemuri P
  • Mielke MM
  • Fields JA
  • Machulda MM
  • Schwarz CG
  • Senjem ML
  • Gunter JL
  • Petersen RC
Neuropathological Findings of Dementia Associated With Subjective Hearing Loss.

  • Neff RM
  • Jicha G
  • Westgate PM
  • Hawk GS
  • Bush ML
  • McNulty B
Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85.

  • Raunio A
  • Kaivola K
  • Tuimala J
  • Kero M
  • Oinas M
  • Polvikoski T
  • Paetau A
  • Tienari PJ
  • Myllykangas L

Press releases, workshop summaries, and editorials

Accelerating Research for Parkinson’s Disease

The Accelerating Medicines Partnership Parkinson's disease (AMP PD) program, launched on Jan 30, 2018, is the most ambitious initiative so far to find a cure for Parkinson's disease. Formed by the US National Institutes of Health (NIH), the US Food and Drug Administration (FDA), five biopharmaceutical and life science companies, and the Michael J. Fox Foundation, this partnership is focused on discovering novel therapeutic targets and on developing biomarkers to help validate existing therapeutic targets for Parkinson's disease.



NIH launches partnership to improve success of clinical trials for patients with Parkinson’s disease

“Advancing treatments for Parkinson’s disease is hampered by insufficient understanding of biological networks; drugs aimed at seemingly promising therapeutic targets fail in clinical trials,” said NIH Director Francis S. Collins, M.D., Ph.D. “By combining our expertise and resources, AMP PD partners hope to increase our collective odds of success in accelerating the development of effective treatments for a million Americans who suffer from this debilitating disease.”